53 results on '"Gevaert, Philippe"'
Search Results
2. Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial
3. The unified airway hypothesis: evidence from specific intervention with anti-interleukin-5 biologic therapy
4. The Indispensable Nasal Decongestant: Patients’ Views and Perspectives on Nasal Decongestant Overuse
5. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology
6. Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)
7. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
8. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
9. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies
10. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
11. Omalizumab Improves Outcomes In Patients With Nasal Polyps Regardless Of Their Asthma Status
12. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study
13. Mepolizumab for chronic rhinosinusitis with nasal polyps
14. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps
15. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
16. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
17. Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study
18. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management
19. Reply
20. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy
21. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
22. Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop
23. Omalizumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Irrespective of Asthma Status
24. Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma
25. Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
26. Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
27. Atopic Comorbidities and Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Failed Intranasal Corticosteroids
28. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps
29. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance
30. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
31. Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray
32. Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial
33. The quest for autoreactive antibodies in nasal polyps
34. Chronic Rhinosinusitis without Nasal Polyps
35. Allergic Sensitization, High Local IL-5 and IgE Predict Surgical Outcome 12 Years after Endoscopic Sinus Surgery for Chronic Rhinosinusitis with Nasal Polyposis
36. Self-Medication in Persistent Rhinitis: Overuse of Decongestants in Half of the Patients
37. Poster 1021: Use of paper filter discs for measurement of local biomarkers of nasal mucosal inflammation
38. Reply
39. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
40. The who, where, and when of IgE in allergic airway disease
41. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
42. Pathogenesis of chronic rhinosinusitis: Inflammation
43. Oral steroids and doxycycline: Two different approaches to treat nasal polyps
44. TGF-β signaling and collagen deposition in chronic rhinosinusitis
45. T-cell regulation in chronic paranasal sinus disease
46. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps
47. Doxycycline reduces ECP, MMP9 and nasal polyp size, in a double-blind, randomized, placebo controlled, multicenter trial
48. Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study
49. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis
50. Increased IgE-antibodies to Staphylococcus aureus enterotoxins in patients with COPD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.